CoChat
Sign Up
Cited by 20Immunotherapy and Immune ResponsesChemical Synthesis and AnalysisAdvancements in Transdermal Drug Delivery

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines

Open access
Song, Kefan, Pun, Suzie H.·2024·BME Frontiers
DOI 10.34133/bmef.0038PMC PMC10956738
Open this paper in CoChat — free account

Abstract

With the recent advances in neoantigen identification, peptide-based cancer vaccines offer substantial potential in the field of immunotherapy. However, rapid clearance, low immunogenicity, and insufficient antigen-presenting cell (APC) uptake limit the efficacy of peptide-based cancer vaccines. This review explores the barriers hindering vaccine efficiency, highlights recent advancements in synthetic delivery systems, and features strategies for the key delivery steps of lymph node (LN) drainage, APC delivery, cross-presentation strategies, and adjuvant incorporation. This paper also discusses the design of preclinical studies evaluating vaccine efficiency, including vaccine administration routes and murine tumor models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.34133/bmef.0038

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 134

  1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. · DOI · Paper page
  2. 10.1038/s41586-023-06063-y · DOI · Paper page
  3. Morse MA, Crosby EJ, Force J, Osada T, Hobeika AC, Hartman ZC, Berglund P, Smith J, Lyerly HK. Clinical trials of self-replicating RNA-based cancer vaccines. Cancer Gene Ther. 2023;30(6):803–811. · DOI
  4. Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, et al. Phase 2 trial of a multivalent WT1 peptide vaccine(Galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224–234. · DOI
  5. Callmann CE, Cole LE, Kusmierz CD, Huang Z, Horiuchi D, Mirkin CA. Tumor cell lysate-loaded Immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. Proc Natl Acad Sci. 2020;117(30):17543–17550. · DOI
  6. 10.1080/15384047.2015.1078027 · DOI
  7. Viborg N, Pavlidis MA, Barrio-Calvo M, Friis S, Trolle T, Sørensen AB, Thygesen CB, Kofoed SV, Kleine-Kohlbrecher D, Hadrup SR, et al. DNA based neoepitope vaccination induces tumor control in syngeneic mouse models. npj Vaccines. 2023;8(1):77. · DOI
  8. Li J, Wu Y, Xiang J, Wang H, Zhuang Q, Wei T, Cao Z, Gu Q, Liu Z, Peng R. Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines. Chem Eng J. 2023;456: Article 140930. · DOI
  9. 10.1038/s41563-018-0028-2 · DOI
  10. 10.1021/acsnano.5b08084 · DOI
  11. 10.1186/s13045-022-01247-x · DOI
  12. 10.1038/s41568-021-00346-0 · DOI · Paper page
  13. 10.1038/nri.2017.131 · DOI · Paper page
  14. 10.1038/s43018-022-00418-6 · DOI
  15. 10.1126/science.2470152 · DOI
  16. You Z, Zhou W, Weng J, Feng H, Liang P, Li Y, Shi F. Application of HER2 peptide vaccines in patients with breast cancer: A systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):489. · DOI
  17. Baba T, Sato-Matsushita M, Kanamoto A, Itoh A, Oyaizu N, Inoue Y, Kawakami Y, Tahara H. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using Gp100-derived epitope peptide restricted to HLA-A*2402. J Transl Med. 2010;8(1):84. · DOI
  18. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. Gp100 peptide vaccine and Interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–2127. · DOI
  19. Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, et al. Neoantigen vaccine: An emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. · DOI
  20. 10.1038/s41573-021-00387-y · DOI
  21. 10.1038/s41586-018-0792-9 · DOI · Paper page
  22. 10.1038/s41591-020-01206-4 · DOI
  23. 10.3390/cancers12071760 · DOI
  24. 10.1158/2159-8290.CD-20-0756 · DOI
  25. Lerner EC, Woroniecka KI, D’Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, Waibl-Polania J, Wachsmuth LP, Miggelbrink AM, Jackson JD, et al. CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL Axis. Nat Cancer. 2023;4(9):1258–1272. · DOI
  26. 10.1038/s41577-019-0210-z · DOI
  27. 10.1038/nri2103 · DOI
  28. 10.1038/s41577-021-00574-3 · DOI · Paper page
  29. Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy—New insights into old paradigms. Cancer Gene Ther. 2021;28(1):5–17. · DOI
  30. 10.1146/annurev-immunol-032712-095910 · DOI
  31. 10.1016/j.immuni.2015.06.023 · DOI
  32. Schwartz RH. T cell anergy. Annual Rev Immunol. 2003;21:305–334. · DOI · Paper page
  33. Pham NL, Badovinac V, Harty J. Differential role of “signal 3” inflammatory cytokines in regulating CD8 T cell expansion and differentiation in vivo. Front Immunol. 2011;2:4.
  34. Wilson NS, el-Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath WR, Shortman K, Villadangos J́A. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood. 2003;102(6):2187–2194. · DOI
  35. 10.1016/j.smim.2007.11.007 · DOI
  36. 10.1016/j.jconrel.2014.04.051 · DOI
  37. 10.1038/s41578-019-0110-7 · DOI
  38. 10.1038/nnano.2017.52 · DOI
  39. 10.1002/anie.202006117 · DOI
  40. 10.1021/acsami.7b06024 · DOI
  41. 10.1038/s41587-019-0390-x · DOI
  42. Mueller SN, Tian S, DeSimone JM. Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity. Mol Pharm. 2015;12(5):1356–1365. · DOI
  43. 10.1126/sciadv.abd7134 · DOI
  44. 10.1016/j.immuni.2014.12.024 · DOI
  45. 10.1021/acs.nanolett.9b02834 · DOI
  46. 10.1021/acsnano.0c02240 · DOI
  47. Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, Zhang H, Ma Y, Zhang F, Tian R, Ni Q, et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017;8(1):1954. · DOI
  48. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, van Egeren DS, Park C, Irvine DJ. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–522. · DOI
  49. van der Zande HJP, Nitsche D, Schlautmann L, Guigas B, Burgdorf S. The mannose receptor: From endocytic receptor and biomarker to regulator of(meta)inflammation. Front Immunol. 2021;12:765034. · DOI
  50. 10.1038/s41563-018-0256-5 · DOI
  51. 10.1021/acs.nanolett.0c01140 · DOI
  52. Yu J, Wang S, Qi J, Yu Z, Xian Y, Liu W, Wang X, Liu C, Wei M. Mannose-modified liposome designed for epitope peptide drug delivery in cancer immunotherapy. Int Immunopharmacol. 2021;101:108148. · DOI
  53. Lv S, Song K, Yen A, Peeler DJ, Nguyen DC, Olshefsky A, Sylvestre M, Srinivasan S, Stayton PS, Pun SH. Well-defined mannosylated polymer for peptide vaccine delivery with enhanced antitumor immunity. Adv Healthc Mater. 2022;11(9): Article e2101651. · DOI
  54. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015;40:88–97. · DOI
  55. Trabbic KR, Kleski KA, Barchi JJ Jr. Stable gold-nanoparticle-based vaccine for the targeted delivery of tumor-associated glycopeptide antigens. ACS Bio Med Chem Au. 2021;1(1):31–43. · DOI
  56. 10.1186/s40035-015-0041-1 · DOI
  57. 10.1038/s41565-020-00782-3 · DOI
  58. 10.1021/nn305466z · DOI
  59. 10.1016/j.biomaterials.2018.07.052 · DOI
  60. 10.1016/j.ejpb.2018.05.034 · DOI
  61. 10.1038/ni.2050 · DOI
  62. 10.1016/j.jconrel.2023.03.004 · DOI
  63. Dingjan I, Verboogen DRJ, Paardekooper LM, Revelo NH, Sittig SP, Visser LJ, Mollard, Henriet SSV, Figdor CG, ter Beest M, et al. Lipid peroxidation causes endosomal antigen release for cross-presentation. Sci Rep. 2016;6(1):22064. · DOI
  64. 10.1021/acsnano.0c05062 · DOI
  65. 10.3389/fphys.2017.00005 · DOI
  66. Yang J, Bahreman A, Daudey G, Bussmann J, Olsthoorn RCL, Kros A. Drug delivery via cell membrane fusion using lipopeptide modified liposomes. ACS Cent Sci. 2016;2(9):621–630. · DOI
  67. 10.3389/fimmu.2018.01643 · DOI
  68. 10.1016/j.cell.2019.09.035 · DOI
  69. 10.1126/science.adg8802 · DOI
  70. 10.1016/j.trecan.2018.09.001 · DOI · Paper page
  71. Yan Z, Wu Y, du J, Li G, Wang S, Cao W, Zhou X, Wu C, Zhang D, Jing X, et al. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy. Oncotarget. 2016;7(26):40437–40450. · DOI
  72. Arabpour M, Paul S, Grauers Wiktorin H, Kaya M, Kiffin R, Lycke N, Hellstrand K, Martner A. An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis. Onco Targets Ther. 2022;11(1):2115618.
  73. Li H, Li Y, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotech. 2011;6(10):645–650. · DOI
  74. 10.1021/mp500066v · DOI
  75. 10.1126/science.1246829 · DOI
  76. Huis in’t Veld LGM, Ho NI, Wassink M, den Brok MH, Adema GJ. Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation. Cell Mol Life Sci. 2022;79(5):231. · DOI
  77. Zhao H, Xu J, Li Y, Guan X, Han X, Xu Y, Zhou H, Peng R, Wang J, Liu Z. Nanoscale coordination polymer based nanovaccine for tumor immunotherapy. ACS Nano. 2019;13(11):13127–13135. · DOI
  78. Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016;4(1):56. · DOI
  79. El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: An overview. Bull Natl Res Cent. 2019;43(1):187. · DOI
  80. 10.4049/jimmunol.1101313 · DOI
  81. 10.4049/jimmunol.1004163 · DOI
  82. 10.1146/annurev-pathol-031920-093932 · DOI
  83. Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol. 2022;94(3):869–877. · DOI
  84. Aichhorn S, Linhardt A, Halfmann A, Nadlinger M, Kirchberger S, Stadler M, Dillinger B, Distel M, Dohnal A, Teasdale I, et al. pH-sensitive macromolecular prodrug as TLR7/8 targeting immune response modifier. Chemistry. 2017;23(70):17721–17726. · DOI
  85. Nguyen DC Song K Jokonya S Yazdani O Sellers DL Wang Y Zakaria A Pun SH Stayton PS. Mannosylated STING agonist drugamers for dendritic cell-mediated cancer immunotherapy. ACS Cent Sci. 2024. · DOI
  86. 10.1126/sciadv.adg2239 · DOI
  87. 10.1111/j.1600-065X.2009.00784.x · DOI
  88. Maldonado RA, LaMothe R, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, Griset AP, O'Neil C, Altreuter DH, Browning E, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci USA. 2015;112(2):E156–E165. · DOI · Paper page
  89. 10.1021/ja3063293 · DOI
  90. 10.1021/acsnano.0c02765 · DOI
  91. 10.1021/acscentsci.5b00274 · DOI
  92. Jin S, Yoo YJ, Shin HS, Kim S, Lee SN, Lee CH, Kim H, Kim JE, Bae YS, Hong JH, et al. A nanoadjuvant that dynamically coordinates innate immune stimuli activation enhances cancer immunotherapy and reduces immune cell exhaustion. Nat Nanotechnol. 2023;18(4):390–402. · DOI
  93. 10.1038/nmat4822 · DOI
  94. 10.1021/acscentsci.9b01174 · DOI
  95. Sultan H, Kumai T, Nagato T, Wu J, Salazar AM, Celis E. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol Immunother. 2019;68(3):455–466. · DOI
  96. 10.1038/s41590-020-00810-3 · DOI
  97. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med. 2013;19(4):465–472. · DOI
  98. Kuai R, Sun X, Yuan W, Xu Y, Schwendeman A, Moon JJ. Subcutaneous nanodisc vaccination with neoantigens for combination cancer immunotherapy. Bioconjug Chem. 2018;29(3):771–775. · DOI
  99. Migliore A, Gigliucci G, Di Marzo R, Russo D, Mammucari M. Intradermal vaccination: A potential tool in the battle against the COVID-19 pandemic? Risk Manag Healthc Policy. 2021;14:2079–2087. · DOI
  100. Kim NW, Kim SY, Lee JE, Yin Y, Lee JH, Lim SY, Kim ES, Duong HTT, Kim HK, Kim S, et al. Enhanced cancer vaccination by in situ nanomicelle-generating dissolving microneedles. ACS Nano. 2018;12(10):9702–9713. · DOI
  101. Johansen P, Häffner A C, Koch F, Zepter K, Erdmann I, Maloy K, Simard J J, Storni T, Senti G, Bot A, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol. 2005;35(2):568–574. · DOI
  102. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, Kündig TM, Gander B, Johansen P. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010;147(3):342–349. · DOI
  103. Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji E, Takaeuchi A, Nagayawa S, et al. Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: A retrospective analysis. Anticancer Res. 2021;41(8):4101–4115. · DOI
  104. Joe PT, Christopoulou I, van Hoecke L, Schepens B, Ysenbaert T, Heirman C, Thielemans K, Saelens X, Aerts JL. Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. J Transl Med. 2019;17(1):242. · DOI
  105. 10.1002/adma.202007293 · DOI
  106. Calderón-Colón X, Zhang Y, Tiburzi O, Wang J, Hou S, Raimondi G, Patrone J. Design and characterization of lipid nanocarriers for oral delivery of immunotherapeutic peptides. J Biomed Mater Res A. 2023;111(7):938–949. · DOI
  107. Francian A, Namen S, Stanley M, Mann K, Martinson H, Kullberg M. Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. Nanomedicine. 2019;18:326–335. · DOI
  108. Snipstad S, Bremnes F, Dehli Haugum M, Sulheim E. Characterization of immune cell populations in syngeneic murine tumor models. Cancer Med. 2023;12(10):11589–11601. · DOI
  109. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, et al. Gp100/Pmel 17 is a murine tumor rejection antigen: Induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188(2):277. · DOI
  110. Bloom M, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185(3):453–460. · DOI
  111. 10.1038/nature14426 · DOI · Paper page
  112. Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, Pei P, Wang C, Wu H, Dong Z, et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020;15(12):1043–1052. · DOI
  113. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother. 2013;36(9):477–489. · DOI
  114. Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci. 1992;89(13):6020–6024. · DOI
  115. Cafri G, Sharbi-Yunger A, Tzehoval E, Eisenbach L. Production of LacZ inducible T cell hybridoma specific for human and mouse Gp10025–33 peptides. PLOS ONE. 2013;8(2): Article e55583. · DOI
  116. Kim MK, Kim J. Properties of immature and mature dendritic cells: Phenotype, morphology, phagocytosis, and migration. RSC Adv. 2019;9(20):11230–11238. · DOI
  117. Mbongue JC, Nieves HA, Torrez TW, Langridge WHR. The role of dendritic cell maturation in the induction of insulin-dependent diabetes mellitus. Front Immunol. 2017;8:327. · DOI
  118. Sharpe AH, Freeman GJ. The B7–CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–126. · DOI
  119. Peeler DJ, Yen A, Luera N, Stayton PS, Pun SH. Lytic polyplex vaccines enhance antigen-specific cytotoxic T cell response through induction of local cell death. Adv Therap. 2021;4(8):2100005. · DOI
  120. 10.1126/sciadv.aaw6071 · DOI
  121. Cheng K, Zhao R, Li Y, Qi Y, Wang Y, Zhang Y, Qin H, Qin Y, Chen L, Li C, et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology. Nat Commun. 2021;12(1):2041. · DOI · Paper page
  122. Ramirez-Valdez RA, Baharom F, Khalilnezhad A, Fussell SC, Hermans DJ, Schrager AM, Tobin KKS, Lynn GM, Khalilnezhad S, Ginhoux F, et al. Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Rep. 2023;42(6): Article 112599. · DOI
  123. 10.1016/j.tcb.2020.06.003 · DOI
  124. 10.1038/nri2343 · DOI · Paper page
  125. 10.1016/j.vaccine.2016.04.081 · DOI
  126. 10.1016/j.jconrel.2022.02.027 · DOI
  127. Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70(6):849–860. · DOI
  128. Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 Oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–1847. · DOI
  129. Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2(1):11. · DOI
  130. Rötzschke O, Falk K, Stevanovic S, Jung G, Walden P, Rammensee HG. Exact prediction of a natural T cell epitope. Eur J Immunol. 1991;21(11):2891–2894. · DOI
  131. 10.1189/jlb.0304120 · DOI
  132. Hos BJ, Tondini E, Camps MGM, Rademaker W, van den Bulk J, Ruano D, Janssen GMC, de Ru AH, van den Elsen PJ, de Miranda NFCC, et al. Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA. Cell Rep. 2022;41(2): Article 111485. · DOI
  133. Feltkamp MC, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, Schegget JT, Melief CJM, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23(9):2242–2249. · DOI
  134. Bahmani B, Amini-bayat Z, Ranjbar MM, Bakhtiari N, Zarnani AH. HPV16-E7 protein T cell epitope prediction and global therapeutic peptide vaccine design based on human leukocyte antigen frequency: An in-silico study. Int J Pept Res Ther. 2021;27(1):365–378. · DOI

Metadata

Authors
Song, K., & Pun, S. H.
Affiliations
University of Washington (US)
ORCID
Venue
BME Frontiers
Publisher
American Association for the Advancement of Science (AAAS)
Published
2024-01
Volume
5
Pages
0038-0038
ISSN
2765-8031 (ISSN-L)
DOI
10.34133/bmef.0038
PMC
PMC10956738
OpenAlex
W4392004055
Cited by
20
References
9
Citations by year
2026: 10 · 2025: 6 · 2024: 4
FWCI
3.09
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BME Frontiers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Cancer Institute (R01CA257563)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
peptide-based cancer vaccines, neoantigens, lymph node drainage, cross-presentation, vaccine adjuvants, vaccine route of administration, mouse tumor model, vaccine immunogenicity, preclinical vaccine evaluation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines. https://app.cochat.ai/papers/10.34133/bmef.0038
The paper
Song, K., & Pun, S. H. (2024). Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines. BME Frontiers. https://doi.org/10.34133/bmef.0038